NET

Clearmind Medicine Completed Type A Meeting with the FDA

Retrieved on: 
Mittwoch, Januar 10, 2024
MEAI, CWY, Serotonin, DAT, Reward, NET, IND, Food, Dopamine, FDA, Therapy, Norepinephrine, Pharmaceutical industry

"We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

Key Points: 
  • "We're pleased to report we recently met with the FDA to align on the content of our IND resubmission for CMND-100," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.
  • The active ingredient in CMND-100 is MEAI (5-methoxy-2-aminoindane), a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
  • MEAI was found to interact with the serotonergic receptors 5-HT1a, 5-HT2a and 5-HT2b.
  • The serotonergic system is considered to play a key role in the regulation of alcohol intake, reward, preference, and dependence.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
Sonntag, Januar 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Associate, Baylor College of Medicine, PKMYT1, BRCA, FDA, Breast, Progression-free survival, Society, Insilico Medicine, Cancer, Distinguishing, Translational research, Neck, PLK4, Workforce, Conference, Translation, Biology, IND, Colorectal cancer, MSN, NHT, University, PARP, Doctor of Philosophy, Calendar, District court, Harvard University, Immunotherapy, Food, Johnson & Johnson, NET, Huntsman Corporation, Cell adhesion, Therapy, TKI, USP1, Neoplasm, Experiment, Patient, NCI, Corporation, Baylor University, Huntsman Cancer Institute, Research, Acquisition, Dean (education), Education, Pnet, Head, Shareholder, Share repurchase, PFS, ADC, Pharmaceutical industry

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

Retrieved on: 
Mittwoch, Dezember 13, 2023
CRC, NET, HKEX, Incidence, Cancer, NRDL, Patient, Senior

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) at the same terms as the current two-year agreement.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanism of the China National Healthcare Security Administration (“NHSA”), on January 1, 2024 the updated National Reimbursement Drug List (“NRDL”) will continue to include ELUNATE® (fruquintinib) and SULANDA® (surufatinib) at the same terms as the current two-year agreement.
  • Mr Hong Chen, Senior Vice President and Chief Commercial Officer (China) of HUTCHMED, said: “The NRDL has made it possible for our innovative medicines to quickly reach more patients in need across China.
  • In the past few years, we have seen an array of new measures adopted by the NHSA, including the NRDL negotiation, the bidding process for non-exclusive medicines and simplified renewal rules for already listed medicines.
  • In China, there were an estimated 71,300 newly diagnosed NET patients in 2020, with potentially up to 300,000 patients living with the disease.2

America’s Car-Mart Reports Second Quarter 2024 Results

Retrieved on: 
Dienstag, Dezember 5, 2023
Online, Marketing, Culture, NET, Acquisition, Ocas, SALES, YOY, Non-commissioned officer, Investment, Environment

This required an increase in the allowance for credit losses which subsequently impacted the bottom line for the quarter.

Key Points: 
  • This required an increase in the allowance for credit losses which subsequently impacted the bottom line for the quarter.
  • SALES – Sales for the quarter were 15,162 units vs. 15,885 units, down 4.6% vs. the prior year quarter.
  • GROSS PROFIT – Gross profit per unit was $6,835 compared to $6,132 for the prior year’s second quarter.
  • SG&A per average account was $429 compared to $439 during the prior year’s second quarter.

Connexa Announces Quarterly and Half Year Results

Retrieved on: 
Dienstag, November 28, 2023
NET, IOS, Pickleball, Heart, Padel, Tennis, Android, Bag, Algorithm

Connexa Records 59 Percent Improvement in Operating Loss for Quarter Ended October 2023 and 72 Percent Improvement Year-to-Date.

Key Points: 
  • Connexa Records 59 Percent Improvement in Operating Loss for Quarter Ended October 2023 and 72 Percent Improvement Year-to-Date.
  • Positive NET INCOME for the 6 Months to October 2023.
  • Windsor Mills, MD, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (Nasdaq:CNXA) reported operating results for the quarter and half year periods ended October 31, 2023 and provided an update and review of operations, including launch of its Slinger Bag AI App for beta testing.
  • “We envision our AI platform as a product and technology that will be at the heart of ‘powering’ the Connexa portfolio of brands.

Perspective Therapeutics Announces First Ever Human SPECT Imaging of Pb-212 with VMT-α-NET by Clinical Collaborators in Germany

Retrieved on: 
Dienstag, November 28, 2023
Molecular imaging, SSTR2, Food, Perspective, NET, Physician, Nuclear medicine, PET/CT, SPECT/CT, Patient safety, NETS, Half-life, Therapy, Liver disease, Neoplasm, Isotope, Noise, Siemens Healthineers, Patient, CATX, Diagnosis, SPECT, European Journal, Institute of technology, DOTATATE, Glomus tumor, Medical imaging

SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the publication of the first human SPECT images utilizing the alpha-emitting isotope of 212Pb, which was labeled to the Company’s proprietary theranostic VMT-α-NET product. The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany. The Company is developing VMT-α-NET for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors.

Key Points: 
  • The imaging was conducted as part of a series of four neuroendocrine tumor (NET) patients who were administered VMT-α-NET at a clinical study site in Germany.
  • VMT-α-NET is being administered under the supervision of Prof. Dr. Jörg Kotzerke, Director of the Department of Nuclear Medicine at the Technical University of Dresden in Germany.
  • The SPECT/CT images showed high accumulation of [212Pb]VMT-α-NET in liver metastases and were consistent with the previously acquired [68Ga]DOTATATE PET/CT.
  • Perspective Therapeutics supplies a generator, drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-α-NET.

Purple Biotech Reports Third Quarter 2023 Financial Results

Retrieved on: 
Dienstag, November 21, 2023
Drug resistance, ADS, Nine Months, Conference, AACR, Neoplasm, Tumor microenvironment, Table, MOA, Nivolumab, NET, Research, Biomarker, CMC, International, Cetuximab, Administration, NETS, Pancreatic cancer, CM24, Serum, Head, Patent, International Financial Reporting Standards, Neutrophil, Insurance, BMS, Average cost, PDAC, Neutrophil extracellular traps, CEACAM1, Net, Bristol Myers Squibb, OS, PFS, Escape Room, Acceleration, Neck, Pharmaceutical industry

REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • REHOVOT, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced financial results for the third quarter and nine months ended September 30, 2023.
  • Recently reported biomarker data demonstrates CM24’s mechanism of action for this important indication in dire need of a more effective drug that prolongs survival,” stated Purple Biotech CEO, Gil Efron.
  • The increase was mainly due to clinical trials expenses in our CM24 study offset by lower CMC costs in 2023.
  • A reconciliation of certain IFRS to non-IFRS financial measures has been provided in the tables included in this press release.

ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market

Retrieved on: 
Dienstag, November 21, 2023
Phase, Map, Treatment, NET, Attention deficit hyperactivity disorder, European, Patent, Ophthalmology, Polygala, Norepinephrine, Norepinephrine transporter, Neurology, Pharmaceutical industry

17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).

Key Points: 
  • 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder (ADHD).
  • "This patent grants ABVC the right to exclude others from using, offering, or selling PDC-1421 throughout the United States until 2040," said Dr. Uttam Patil, ABVC Chief Executive Officer .
  • ABVC submitted the patent application to the United States Patent and Trademark Office under "Polygala Extract for the Treatment of ADHD."
  • According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period.1

Robbins Geller Rudman & Dowd LLP and Kahn Swick & Foti, LLC Announce Proposed Settlement in the Cleco Merger Litigation

Retrieved on: 
Donnerstag, Dezember 21, 2023
Legal, Professional Services, Claim, Parish, ACTION, NET, Class, Allocation, Court, CLASS, Ninth, YOU, Class Action, REAL, Settlement, Post office box, CLECO, PER, Murray Street, Hearing, COMMON, Judgement, Cryptocurrency

CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.

Key Points: 
  • CERTAIN PERSONS ARE EXCLUDED FROM THE DEFINITION OF THE CLASS AS SET FORTH IN THE STIPULATION OF SETTLEMENT.
  • YOUR RIGHTS MAY BE AFFECTED BY A CLASS ACTION LAWSUIT PENDING IN THIS COURT.
  • You may also obtain copies of the Stipulation of Settlement, Notice, and Proof of Claim at www.ClecoMergerSettlement.com .
  • If you previously excluded yourself from the Class, you will have no right to recover money pursuant to the Settlement.

Nexus Development Capital Adds Carbon Removal to Growing Portfolio with a $5M Investment in Maine-based Standard Biocarbon

Retrieved on: 
Donnerstag, Dezember 21, 2023
Nexus, CDR, NET, Research, Heat, Polymer, Temperature, Growth, Carbon, FOAK, CO2, Agriculture

NEW YORK, Dec. 21, 2023 /PRNewswire/ -- Nexus Development Capital, a provider of catalytic capital for sustainable infrastructure project developers, today announced a $5M investment in biochar producer Standard Biocarbon. The funding will enable Standard Biocarbon to scale operations at its facility in Enfield, Maine to meet the growing demand for carbon capture and biochar. The company will commence production of its high-quality biochar in Q1 2024 and is estimated to produce 16,000 cubic yards of biochar and capture 3,000 tons of carbon a year.

Key Points: 
  • NEW YORK, Dec. 21, 2023 /PRNewswire/ -- Nexus Development Capital , a provider of catalytic capital for sustainable infrastructure project developers, today announced a $5M investment in biochar producer Standard Biocarbon .
  • The funding will enable Standard Biocarbon to scale operations at its facility in Enfield, Maine to meet the growing demand for carbon capture and biochar.
  • Scaling these types of carbon removal facilities is now one of our biggest opportunities," said Joshua Kaufman, CEO of Nexus Development Capital.
  • "This investment by Nexus Development Capital has enabled Standard Biocarbon to complete one of the most advanced and efficient biochar plants in the world," said Fred Horton, CEO and co-founder of Standard Biocarbon.